ALK and non-small cell lung carcinoma: We focused on real-world systemic anticancer therapy utilization, OS and rwPFS outcomes for patients diagnosed with stage IIIBrp/IV NSCLC with EGFR, ALK and ROS1 statuses of negative or unknown, grouping the overall population into two cohorts, based on 1L treatment started prior to or after pembrolizumab became the standard of care in the Emilia-Romagna region.